Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2)

Main Article Content

Laura K Ferris
April W Armstrong
James Del Rosso
Zoe D Draelos
Melinda Gooderham
Mark Lebwohl
Kim A Papp
Jennifer Soung
Linda Stein Gold
David Krupa
Robert C Higham
Patrick Burnett
David R Berk

Keywords

roflumilast, cream, psoriasis, toleratbility, intertriginous, phase 3 trial

Abstract

N/A

References

1. Merola JF, et al. Dermatol Ther 2018;31:e12589.

2. Elmets CA, et al. J Am Acad Dermatol 2021;84:432–470.

3. Dong C, et al. J Pharmacol Exp Ther 2016;358:413–422.

4. Lebwohl MG, et al. N Engl J Med 2020;383:229–239.

5. Lebwohl MG, et al. 30th Congress of the European Academy of Dermatology and Venereology (EADV) Virtual, September 29–October 2, 2021.

6. Lebwohl MG, et al. American Academy of Dermatology (AAD), Boston, MA, March 25–29, 2022.

Most read articles by the same author(s)

<< < 22 23 24 25 26 27